InvestorsHub Logo
Followers 18
Posts 346
Boards Moderated 0
Alias Born 04/17/2013

Re: None

Saturday, 02/01/2014 10:34:54 AM

Saturday, February 01, 2014 10:34:54 AM

Post# of 130503
Interesting interview with Dr. Rubinfeld from 15 years ago regarding his company, SuperGen (later Astex and then acquired by Otsuka a few months ago). The parallels in apparent strategy he described then and Amarantus now are striking.

http://www.twst.com/interview/2184

The section that caught my attention:

"Most companies engaged in partnerships early on in the game, gave away almost all of their rights to everything that they were producing in the future. So they were dependent on other people giving them money and not being able to carry on their own. We have a different paradigm. We own our entire portfolio; this is completely different than most other biotech companies. We also have a very diversified portfolio. We don't believe that you should put all your eggs in one basket and have just one lead compound, because if that fails, you're out of business. We also believe that you have to have at least one late-stage blockbuster compound, as well as a platform technology that's diversified and it turns out we have both."

Sound familiar?